Drug-drug synthetic lethality to combat cancer: From bench to bedside

Clin Transl Med. 2023 May;13(5):e1269. doi: 10.1002/ctm2.1269.

Authors

Yu Chen¹, Wu Yang^{1

2}, Jiaojiao Zheng¹, René Bernards^{1

2}, Haojie Jin^{1

2}

Affiliations

¹ State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

No abstract available

Keywords: Cancer therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Neoplasms* / drug therapy
Neoplasms* / genetics
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Synthetic Lethal Mutations*

Substances

Poly(ADP-ribose) Polymerase Inhibitors